Ambrosia Biosciences is a privately held drug discovery company developing orally delivered, small molecule-based therapies for obesity and other metabolic disorders.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/20/24 | $16,000,000 | Series A |
Boulder Ventures BVF Partners | undisclosed |
